Haemophilia is an X-linked hereditary bleeding disorder that is characterized by problems with blood clotting as a result of the body not being able to produce working clotting factors, which can have potentially life threatening complications.

As an x-linked disease, haemophilia predominantly affects men, and haemophilia A is approximately four times more common than haemophilia B. Haemophilia A also varies in the severity of the condition, with more severe cases being more likely to have poorer health outcomes. GlobalData epidemiologists analyzed haemophilia epidemiology trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and found that most cases of haemophilia A in the US are severe, while in other markets mild cases are more prevalent.

Figure 1 presents the number of diagnosed prevalent cases of haemophilia A by severity in the 7MM in 2016.

In the 7MM, GlobalData epidemiologists forecast that there were 41,490 diagnosed prevalent cases of haemophilia A in 2016. Of those, 19,381 cases were classified as severe, while 15,938 were considered mild. In 2016, the US had the highest number of prevalent cases of haemophilia A with severe type among the 7MM.

Details about this forecast and other discussions of the epidemiology of haemophilia can be found in GlobalData’s EpiCast Report: Haemophilia – Epidemiology Forecast to 2026 and GlobalData’s EpiCast Model: Haemophilia – Epidemiology Forecast to 2026.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Reports

GlobalData (2017). EpiCast Report: Haemophilia – Epidemiology Forecast to 2026, July 2017, GDHCER151-17

GlobalData (2017). EpiCast Model: Haemophilia – Epidemiology Forecast to 2026, July 2017, GDHCEM151-17